ArticleClinical ophthalmology (Auckland, N.Z.)2022
Photorefraction Screening Plus Atropine Treatment for Myopia is Cost-Effective: A Proof-of-Concept Markov Analysis.
Article in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review.Journal of global health · 2025Pooled it
- Interventions for myopia control in children: a living systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Cost-effectiveness analysis of myopia management: A systematic review.Frontiers in public health · 2023Pooled it
- Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective.PharmacoEconomics · 2026Article
- Knowledge, attitude, and practice among parents of myopic children regarding multifocal soft contact lenses.BMC public health · 2025Article
- Childhood Myopia Part II: Treatment Mechanisms, Emerging Options, and Considerations.Investigative ophthalmology & visual science · 2025Review
- Cost-effectiveness of myopia-control spectacles and contact lenses for children and adolescents in Wales.Cost effectiveness and resource allocation : C/E · 2025Article
- Pharmaceutical Prescribing Privileges for Optometrists to Combat Childhood Myopia in Singapore: Public Health Policy Review and Analysis.Children (Basel, Switzerland) · 2024Review
- Lifetime cost-effectiveness of myopia control intervention for the children population.Journal of global health · 2024Article
- Cost-Effectiveness Analysis of Myopia Progression Interventions in Children.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The prevalence of myopia is increasing globally, putting individuals at risk of myopia-associated visual impairment. Low-dose atropine eye drops have been found to safely reduce the risk of progression from myopia to higher levels of myopia and pathological states. In New Zealand, school children have an eye check at age 11. In this study, we aimed to estimate the cost-effectiveness of introducing photorefractive screening for myopia at age 11 in the New Zealand context, with atropine 0.01% eye drops treatment for those screening positive. Patients and Methods: A Markov cohort simulation was used to model the impact of screening plus atropine compared to usual care across a lifetime horizon and societal perspective with a 3% discount rate. Cost-effectiveness was determined by the incremental cost-effectiveness ratio (ICER), with utility measured in quality-adjusted life-years (QALYs). Multivariate sensitivity analyses were carried out to investigate factors influencing cost-effectiveness. Results: The ICER for screening plus atropine was NZ$1590 (95% CI 1390, 1791) per QALY gained, with 7 cases of lifetime blindness prevented per 100,000 children screened. Conclusion: Screening for myopia with photorefraction at age 11 and atropine 0.01% eye drop treatment of children screening positive is likely to be cost-effective. These results suggest that a real-world trial and cost-effectiveness analysis would be worth considering in New Zealand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.